Producer
Roche Diagnostics
Diagnostic division of F. Hoffmann-La Roche (Basel, Switzerland); manufactures viral RNA extraction kits including the High Pure Viral RNA Kit and MagNA Pure series; integrated with Roche cobas PCR system for automated end-to-end COVID testing; ~10-12% of RNA extraction kit market; manufacturing in Mannheim, Germany (primary) and Penzberg, Bavaria; FDA approved the Roche extraction kit as an alternative to Qiagen during COVID, but Roche was also on backorder simultaneously
2
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
2 inputs Roche Diagnostics supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Roche Diagnostics makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Molecular Diagnostics (PCR, NGS)
35%Tissue Diagnostics (Pathology)
20%Clinical Chemistry & Immunoassay
25%Point of Care
10%Life Science Research
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Origin2023
Roche Diagnostics is a division of F. Hoffmann-La Roche AG, founded in 1896 in Basel, Switzerland by Fritz Hoffmann-La Roche with a vision of industrially manufacturing standardized pharmaceutical products rather than compounding them individually in pharmacies. The founding was controversial -- established pharmacists resisted the disruption of the compounding model. Roche became a pharmaceutical powerhouse through the 20th century (inventing Valium, Librium; developing the first HIV treatments), and built its diagnostics division in part through the acquisition of Boehringer Mannheim in 1997 for $11 billion -- at the time the largest-ever acquisition in the life sciences industry. Boehringer Mannheim's diagnostics business became Roche Diagnostics. The PCR technology that underlies Roche's molecular diagnostics came from Cetus Corporation, whose PCR patent Roche licensed in 1992 for $300 million -- the licensing fee for one of the most valuable chemistry patents in history, which made possible all modern molecular diagnostics including COVID-19 tests.
F. Hoffmann-La Roche Ltd. ↗